ALPEGA-GROUP
Alpega Group, a leading European SaaS software company for the transportation industry, announced today that it has reached an agreement to acquire Road Heroes, Truck Driver Platform from Pinetco. Road Heroes is a specialized job site that links truck drivers with prospective employers.
With the current global supply chain strain, shortages of drivers is increasingly creating the bottleneck that will not go away once production ramps to otherwise open supply chains back up. While Alpega provides shippers the opportunity to contract carriers long term, to spot bid through its TMS solutions and manages some of the largest freight exchanges in Europe, the problem of driver shortage is still a blocking point in the chain.
It is estimated that Europe has a shortage of 400,000 truck drivers today. The reasons for this are well documented ranging from a generational retirement of older drivers, lack of work/life balance sought by younger drivers, difficulties of work environment due to road congestion and even lack of parking for trucks in major cities. Many younger people who might be interested in driving have just said ‘no thanks’.
Road Heroes by Alpega provides a European-wide platform for hiring companies and prospective drivers to showcase ‘why us’ and ‘why me’, in an effort to give both parties a competitive edge to fulfil the market needs. The platform comes with a lot of intelligence under the hood, which allows a specific matching between job offers and truck drivers to maximize the relevance.
Efficiency of supply chains, specifically the transportation leg of the supply chain, is increasingly becoming a focus as demand for goods grows, congestion on the motorways skyrockets and inflation hits every pocketbook in the world. Add to this, the environmental impact of empty trucks on the road and the unnecessary carbon emissions those trucks produce.
Being able to have the right trucks at the right place at the right time with full loads, loaded and unloaded as efficiently as possible and then allowing those trucks to take the next load to the next location without downtime or ‘empty backhauls’ helps ease the supply chain strain.
”At Alpega we view our responsibility to the transportation industry as a holistic one involving people, processes and the software tools to move goods as efficiently as possible. Connecting our driver community with our carrier, freight forwarder and shipper communities is a role we are willing and able to play and a natural fit for us. Road Heroes is a next step in our effort to build the largest digital logistics platform in Europe” said Fabrice Douteaud, General Manager, Alpega Freight Exchanges.
The Road Heroes transaction is expected to close in June with availability of Road Heroes by Alpega targeted for July.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
